OncLive TV

Robert L. Ferris, MD, PhD, discusses ongoing research with STING agonists and checkpoint inhibitors in head and neck cancer.

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Sam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.

Andrew J. Armstrong, MD, discusses the utility of PARP inhibitors in mutated prostate cancer.

Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.

Richard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Himisha Beltran, MD, discusses the limitations of tissue biopsies versus liquid biopsies in castration-resistant neuroendocrine prostate cancer.

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Ragini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Robert L. Ferris, MD, PhD, director of University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Hillman Professor of Oncology, associate vice chancellor for cancer research, professor of otolaryngology, immunology, and radiation oncology, co-director, Tumor Microenvironment Center, UPMC Hillman Cancer Center, discusses a clinical trial testing ADU-S100/MIW815 plus pembrolizumab (Keytruda) in patients with head and neck cancer.

Hirva Mamdani, MD, discusses the need to develop novel therapies in locally advanced esophageal and gastroesophageal junction adenocarcinoma.

Sharyn Lewin, MD, FACS, discusses the utility of hyperthermic intraperitoneal chemotherapy in newly diagnosed advanced-stage ovarian cancer.

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.

Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.

Hyman B. Muss, MD, sheds light on how the COVID-19 pandemic is impacting elderly patients with breast cancer and explains why geriatric patients are at a heightened risk of developing severe complications from the virus.

Chris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses current testing patterns in urology practices.

James L. Mohler, MD, professor of oncology, associate director, and senior vice president of Translational Research, chief of Inter-Institutional Academics at Roswell Park Comprehensive Cancer Center, discusses recommendations for performing genetic testing in prostate cancer.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).

Noopur Raje, MD, discusses future research with bispecific T-cell engagers in multiple myeloma.

Terrence J. Bradley, MD, discusses the challenges of treating patients with myeloproliferative neoplasms.

Himisha Beltran, MD, discusses profiling of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Bhavana Pothuri, MD, discusses the importance of obtaining patient-reported outcomes in ovarian cancer.

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

Noopur Raje, MD, discusses the potential utility of belantamab mafodotin in multiple myeloma.